ESMO: Novartis, Daiichi, Gilead, Astellas and AZ excel in analysis of clinical value added from new cancer approvals 0 13.09.2024 14:38 Fiercepharma.com ESMO: Novartis, Daiichi, Gilead, Astellas and AZ excel in analysis of clinical value added from new cancer approvals kdunleavy Fri, 09/13/2024 - 07:38 Moscow.media Частные объявления сегодня Rss.plus Все новости за 24 часа
